Barinthus Biotherapeutics
BRNS
19 hedge funds and large institutions have $58.3M invested in Barinthus Biotherapeutics in 2021 Q2 according to their latest regulatory filings, with 19 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
13.49% more ownership
Funds ownership: 0% → 13.49% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Alphabet Inc
Mountain View,
California
|
+$25.2M |
| 2 |
MGIM
M&G Investment Management
London,
United Kingdom
|
+$16.1M |
| 3 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$6.22M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$2.8M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$1.96M |
Top Sellers
BRNS Hedge Fund Activity: Q2 2021 in Review
19 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q2 2021, worth a combined $58.3M.
Buyers outnumbered sellers: 19 funds opened new BRNS positions and 0 closed out — a net gain of 19 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Alphabet Inc, opening a new position worth an estimated $25.2M.
- 19 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $58.3M of Barinthus Biotherapeutics stock for Q2 2021.
- 19 funds opened new Barinthus Biotherapeutics positions in Q2 2021 and 0 closed out, a net change of +19 holders.
- The largest Barinthus Biotherapeutics buyer in Q2 2021 was Alphabet Inc, an estimated $25.2M added.
Based on aggregated 13F filings for Q2 2021.